ALK and non-small cell lung carcinoma: This analysis assesses the efficacy of brigatinib, a next-generation ALK inhibitor in ALK+ advanced non-small cell lung cancer (aNSCLC) included in the brigatinib French Early-Access Program (1 August 2016–21 January 2019), with a focus on post-brigatinib lorlatinib efficacy.